TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00702078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: closer collaboration between hospital and primary healthcare system
Description: Follow-up from the hospital and the primary healthcare in cooperation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: usual care
Description: follow-up according to todays best practice
Study: NCT04264897

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Silicified microcrystalline cellulose, Micosolle®, K30 povidone, sodium starch glycolate, and magnesium stearate
Study: NCT00807560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FBT-PO
Description: The goal of FBT-PO is to resolve the eating disorder and return the patient to healthy psychosocial and physiological developmental trajectories through active family involvement across three treatment phases.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NEC
Description: Families assigned to NEC will receive a minimal nutrition and physical activity education curriculum across 16 sessions over 24 weeks.
Study: NCT00233454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Midostaurin is a broad-spectrum protein kinase inhibitor, acting on conventional PKC isoforms (α, β, γ); PDFRβ; VEGFR2; Syk; PKCη; Flk-1; Flt3; Cdk1/B; PKA; c-Kit; c-Fgr; c-Src; VEGFR1; and EGFR
Study: NCT02931669

Intervention type: OTHER
Intervention: Qualitative Descriptive Study

Intervention type: OTHER
Intervention: Qualitative Descriptive Study

Intervention type: OTHER
Intervention: Qualitative Descriptive Study

Intervention type: OTHER
Intervention: Qualitative Descriptive Study

Intervention type: OTHER
Intervention: Qualitative Descriptive Study
Study: NCT01643785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second-line quadruple therapy with endonase
Description: Compare Second-line quadruple therapy w/o pronase (endonase)
Study: NCT01209182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Testing a new device (LS BioPath TOUCH) on excised tissue
Description: Measurements are obtained with test device on excised tissue.
Study: NCT04382014

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MAG fish oil + Curcumin OR Rice bran oil + Curcumin OR Curcumin extract
Description: The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) curcumin combined with MAG fish oil as a carrier, 2) curcumin combined with rice bran oil as a carrier, and 3) curcumin extract.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24h after taking the supplement. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MAG fish oil + Curcumin OR Rice bran oil + Curcumin OR Curcumin extract
Description: The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) curcumin combined with MAG fish oil as a carrier, 2) curcumin combined with rice bran oil as a carrier, and 3) curcumin extract.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24h after taking the supplement. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MAG fish oil + Curcumin OR Rice bran oil + Curcumin OR Curcumin extract
Description: The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) curcumin combined with MAG fish oil as a carrier, 2) curcumin combined with rice bran oil as a carrier, and 3) curcumin extract.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24h after taking the supplement. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants.
Study: NCT01733303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized core muscle training program
Description: Participants are allocated to the exercise group will commence the personalized core training exercise with EMG biofeedback based on their testing results in muscle quality. The program will run for 3 months with patients attending for one hour three times a week. The age-matched control group will maintain their usual daily life activities without any specific instruction. The exercise training will be run by an experienced physiotherapist, who will encourage patients individually to progress at their own pace.
Study: NCT03236324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided nerve block
Description: Transversalis fascia plane (TFP) block, ultrasound-guided

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound-guided nerve block
Description: Transversalis fascia plane (TFP) block, ultrasound-guided

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 20 mL 0.9% saline administered on each side as bilateral TFP blocks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-epinephrine
Description: 20 mL bupivacaine 0.25% with epinephrine 2.5 mcg/mL to a maximum of 2.5mg/kg administered on each side as bilateral TFP blocks
Study: NCT02857348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Night Shift
Description: Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Module
Description: The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then complete questions in the Trauma Life Support MCQ Review, spending at least 1 hour on the combined tasks.
Study: NCT02642055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuro+ Attention Training
Description: Attention training program with Neuro+ software

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Continuation of current ADHD treatment
Study: NCT02882750

Intervention type: OTHER
Intervention: EORTC QLQ-C30 (version 3.0).
Description: Quality of Life Questionnaire

Intervention type: OTHER
Intervention: EORTC QLQ-C30 (version 3.0).
Description: Quality of Life Questionnaire

Intervention type: OTHER
Intervention: PS Q18
Description: Patients Satisfaction Questionnaire

Intervention type: OTHER
Intervention: PS Q18
Description: Patients Satisfaction Questionnaire

Intervention type: OTHER
Intervention: Decision Self-Efficacy Scale
Description: Questionnaire

Intervention type: OTHER
Intervention: Decision Self-Efficacy Scale
Description: Questionnaire
Study: NCT03462511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HABIT Intervention
Description: Dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care used to treat patients with SCD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care used to treat patients with SCD

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education materials
Description: Education materials provided to all patients enrolled in the trial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education materials
Description: Education materials provided to all patients enrolled in the trial
Study: NCT03961698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549 (eganelisib)
Description: IPI-549 is an oral, selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-gamma). It is an orally-administered capsule that will be dosed at either 20mg/day, 30mg/day, or 40mg/day to patients in both cohorts A and B depending on the results of the safety run-in phase for each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-549 (eganelisib)
Description: IPI-549 is an oral, selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-gamma). It is an orally-administered capsule that will be dosed at either 20mg/day, 30mg/day, or 40mg/day to patients in both cohorts A and B depending on the results of the safety run-in phase for each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). 840 mg of the drug will be administered intravenously (IV) on days 1 and 15 in combination of each 28-day cycle for patients with TNBC. 1200mg will be administered IV on day 1 of each 21-day cycle to patients with RCC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). 840 mg of the drug will be administered intravenously (IV) on days 1 and 15 in combination of each 28-day cycle for patients with TNBC. 1200mg will be administered IV on day 1 of each 21-day cycle to patients with RCC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel (Taxol), a mitotic inhibitor chemotherapy, with less toxicity than solvent-based (sb) paclitaxel and achieves a 33% higher tumor uptake in preclinical models. Nab-paclitaxel will be administered intravenously (IV) at 100 mg/m2 on days 1, 8 and 15 of each 28-day cycle for patients with TNBC.
Study: NCT03180775

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methionine
Description: Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Methionine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamate
Description: Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glutamate will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glutamine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
Study: NCT01893398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidimensional stimulation group therapy
Description: The MST program involved three levels of treatment. The first level was focused on PWA, the second level involved the caregiver, while the third one the dyad PWA-caregiver.
Study: NCT02867761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indacaterol/Glycopyrrolate
Description: 27.5/15.6 mcg active indacaterol/glycopyrrolate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 27.5/15.6 mcg placebo
Study: NCT04979754

Intervention type: OTHER
Intervention: standard of care
Description: retrospective study : standard of care

Intervention type: OTHER
Intervention: standard of care
Description: retrospective study : standard of care
Study: NCT02180893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paravertebral Block
Description: Paravertebral nerve block injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: No block~Patients who did not receive PVB
Study: NCT04598373

Intervention type: BEHAVIORAL
Intervention: interdisciplinary treatment
Description: Interdisciplinary treatment (IDT) distinguishes itself as an interdisciplinary-coordinated (e.g., physician, occupational therapist, physiotherapist, and psychologist) intervention using a bio-psycho-social view of chronic pain. The MMR continues over a lengthy period with a common goal and generally includes patient education, supervised physical activity, simulated work training, and cognitive behavioural therapy (CBT). The exact composition of these MMR components depends on initial evaluations of the patients health status and furhter follow-up testing. The MMR interventional components can act independently and interdependently, resulting in combined effects due to known and unknown mechanisms; the effects are intended to be greater than the sum of its components.
Study: NCT01625273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei paracasei strain F19
Description: Provided in an infant formula, 10\^8 CFU per day from 28 days to 6 months of infant age
Study: NCT03083028

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non Operative
Description: Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction internal fixation of the ankl
Description: The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
Study: NCT00626093

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac Resynchronization Therapy - Defibrillator (CRT-D)
Description: * Patients in the study who receive Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for Cardiac Resynchronization Therapy (CRT).~* Patient undergoes Defibrillation threshold (DFT) testing at implant and at 6 months. Defibrillation threshold (DFT) testing will include 3 ventricular fibrillation (VF) inductions.
Study: NCT03708055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo weight bearing exercise program
Study: NCT02396810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intra-operative MRI
Description: Intra-operative magnetic resonance imaging under general anesthesia

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transsphenoidal resection of pituitary macroadenoma
Description: Routine transsphenoidal resection of pituitary macro adenomas

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transsphenoidal resection of pituitary macroadenoma
Description: Routine transsphenoidal resection of pituitary macro adenomas
Study: NCT02456428

Intervention type: DRUG
Intervention: DPP-4 inhibitors
Description: Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.

Intervention type: DRUG
Intervention: GLP-1 analogs
Description: Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.

Intervention type: DRUG
Intervention: Insulins
Description: Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.

Intervention type: DRUG
Intervention: Biguanides
Description: Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.

Intervention type: DRUG
Intervention: Biguanides
Description: Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.

Intervention type: DRUG
Intervention: Sulfonylureas
Description: Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Study: NCT03961698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is an anti-vascular endothelial growth factor (anti-VEGF) recombinant monoclonal antibody that is approved by the FDA for the treatment of multiple solid tumors in combination with chemotherapy. It will be administered at 15 mg/kg IV on day 1 of each 21-day cycle to patients with RCC.
Study: NCT03216434

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI using DaTscan
Description: A standard, non-contrast-enhanced structural/anatomic brain MRI will be performed. It will be used to exclude potential subjects and controls with significant and potentially confounding structural/anatomic findings. It will also be used as an anatomic overlay with the functional DaTscan image to aid in anatomic/physiologic correlation. At the same imaging session, a brief functional MRI (not requiring the subject to perform any tasks) will also be performed.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI using DaTscan
Description: A standard, non-contrast-enhanced structural/anatomic brain MRI will be performed. It will be used to exclude potential subjects and controls with significant and potentially confounding structural/anatomic findings. It will also be used as an anatomic overlay with the functional DaTscan image to aid in anatomic/physiologic correlation. At the same imaging session, a brief functional MRI (not requiring the subject to perform any tasks) will also be performed.
Study: NCT02500056

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optilene LP mesh
Description: Lichtenstein hernioplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrapro mesh
Description: Lichtenstein hernioplasty
Study: NCT02760225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-Pembrolizumab
Description: In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 89Zr-Pembrolizumab PET
Description: In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
Study: NCT04228159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance Tutor Biofeedback Rehabilitation System
Description: Balance Tutor system is a unique technology which allows for several postural control ability assessments as well as reactive response training in both standing and walking using controlled perturbation in simple task or multitask performance. Together with proactive training the system allows for optimal rehabilitation outcome and recovery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance and strengthening exercise
Description: exercise training programs for fall prevention including walking and balance exercises, functional tasks, strength, flexibility and endurance
Study: NCT02720354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]-DMDPA
Study: NCT03816709

Intervention type: DEVICE
Group type: OTHER
Intervention: Therapeutic Ultrasound
Description: A therapeutic ultrasound treatment was applied to the left medial gastrocnemius muscle with the following parameters: 3 MHz, 1.0 W/cm2 for 15 minutes.